Conclusion Fluoxetine was not statistically different in either tolerability or efficacy when compared with duloxetine .
Venlafaxine was significantly superior to duloxetine in all analyses except dropout rate .
In the absence of relevant data from head-to-head comparison trials , results suggest that venlafaxine is superior compared with duloxetine and that duloxetine does not differentiate from fluoxetine
Background Data comparing duloxetine with existing antidepressant treatments is limited .
A comparison of duloxetine with fluoxetine has been performed but no comparison with venlafaxine , the other antidepressant in the same therapeutic class with a significant market share , has been undertaken .
In the absence of relevant data to assess the place that duloxetine should occupy in the therapeutic arsenal , indirect comparisons are the most rigorous way to go .
We conducted a systematic review of the efficacy of duloxetine , fluoxetine and venlafaxine versus placebo in the treatment of Major Depressive Disorder ( MDD ) , and performed indirect comparisons through meta-regressions .
Placebo‐Controlled Trial of Venlafaxine for the Treatment of Major Depression
Results are presented of the first double-blind , placebo-controlled trial of a novel antidepressant venlafaxine , which pre clinical ly has demonstrated serotonin , norepinephrine , and dopamine reuptake inhibiting effects . Sixty out patients meeting DSM-III-R criteria for major depression were r and omized to receive 6 weeks of treatment with one of three fixed doses of venlafaxine—25 mg three times a day , 75 mg three times a day , or 125 mg three times a day — or placebo . Significant improvement was observed in depression scores at all doses , with the high dose result ing in earlier improvement , by week 2 . For the combined venlafaxine treatment groups , 68 % achieved a moderate or marked improvement on the Clinical Global Impression scale , compared with only 31 % for the placebo group . Venlafaxine was well tolerated , and nervousness , sweating , and nausea were the only adverse effects observed more frequently with drug compared with placebo
Conclusion Fluoxetine was not statistically different in either tolerability or efficacy when compared with duloxetine .
Venlafaxine was significantly superior to duloxetine in all analyses except dropout rate .
In the absence of relevant data from head-to-head comparison trials , results suggest that venlafaxine is superior compared with duloxetine and that duloxetine does not differentiate from fluoxetine
Background Data comparing duloxetine with existing antidepressant treatments is limited .
A comparison of duloxetine with fluoxetine has been performed but no comparison with venlafaxine , the other antidepressant in the same therapeutic class with a significant market share , has been undertaken .
In the absence of relevant data to assess the place that duloxetine should occupy in the therapeutic arsenal , indirect comparisons are the most rigorous way to go .
We conducted a systematic review of the efficacy of duloxetine , fluoxetine and venlafaxine versus placebo in the treatment of Major Depressive Disorder ( MDD ) , and performed indirect comparisons through meta-regressions .